Isidoro Zarco, MD
Ophthalmology · Miami, FLNPI 1710903141
Payments from drug & device makers
Across 229 payments — averaging $50.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$2K
- Bausch & Lomb Americas Inc.$955
- Aerie Pharmaceuticals, Inc.$785
- Bausch & Lomb, A Division Of Bausch Health US, LLC$693
- Sun Pharmaceutical Industries Inc.$642
- plus $2K from 20 others
What the payments were for
- Food & beverage$11,599100%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 57 | $4,175 |
| AbbVie(2 entities) | 77 | $2,317 |
| Bausch & Lomb Americas Inc. | 11 | $955 |
| Aerie Pharmaceuticals, Inc. | 14 | $785 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $693 |
| Sun Pharmaceutical Industries Inc. | 11 | $642 |
| NEW World Medical,inc. | 3 | $330 |
| Novartis | 11 | $257 |
| Kala Pharmaceuticals, Inc. | 3 | $255 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $246 |
| Eyevance Pharmaceuticals LLC | 4 | $155 |
| Dompe US, Inc. | 1 | $148 |
| Omeros Corporation | 1 | $125 |
| Tarsus Pharmaceuticals, Inc. | 4 | $99 |
| Mallinckrodt Hospital Products Inc. | 4 | $93 |
| Amgen | 3 | $57 |
| Thea Pharma Inc. | 3 | $49 |
| Carl Zeiss Meditec USA, Inc. | 1 | $44 |
| Oyster Point Pharma, Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $38 |
| Biotissue Holdings Inc. | 2 | $31 |
| Rayner Intraocular Lenses Limited | 1 | $22 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Alimera Sciences, Inc. | 1 | $15 |
| Akorn, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$1,727
- MIEBO$874
- XIIDRA$861
- Rocklatan$721
- Rhopressa$599
- Clareon PanOptix Pro$402
- LOTEMAX SM$375
- PanOptix$258
- RESTASIS$252
- Tecnis Symfony IOL$246
- VUITY$236
- Oxervate$148
- Unity$139
- Kahook Dual Blade$138
- Clearpath$138
- Ahmed Glaucoma Valve$138
- Streamline$138
- Via360$138
- Constellation$135
- OMIDRIA$125
How this compares
$11,619 in reported general payments places this provider in the 80th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 541 | $174,654 |
| RestasisCyclosporine | 132 | $137,038 |
| XiidraLifitegrast | 77 | $86,424 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 328 | $31,571 |
| CombiganBrimonidine Tartrate/Timolol | 118 | $30,750 |
| IlevroNepafenac | 72 | $27,567 |
| RocklatanNetarsudil Mesylat/Latanoprost | 63 | $26,648 |
| ProlensaBromfenac Sodium | 66 | $23,660 |
| Travoprost | 176 | $21,581 |
| VyzultaLatanoprostene Bunod | 51 | $17,823 |
| Cyclosporine | 29 | $16,067 |
| RhopressaNetarsudil Mesylate | 39 | $12,369 |
| Prednisolone Acetate | 365 | $12,207 |
| Difluprednate | 113 | $9,864 |
| Alphagan PBrimonidine Tartrate | 45 | $9,483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $2,317 | $351,925836 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $955 | $104,247128 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Lotemax, Loteprednol Etabonate | $693 | $39,114126 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $785 | $39,017102 claims |
| NovartisIlevro | $257 | $27,56772 claims |
| AlconSimbrinza, Azopt | $4,175 | $13,44857 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Miami
- Guillermo AmescuaMiami$962K
- Felipe MedeirosMiami$935K
- Jennifer LohMiami$606K
- Jaclyn KovachMiami$590K
- William TrattlerMiami$580K
- Wilfredo LaraMiami$526K
- Jayanth SridharMiami$525K
- Kendall DonaldsonMiami$351K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.